Omega-3 fatty acids and major depression: a Mendelian randomization study

R. Carnegie,M. C. Borges,H. J. Jones,J. Zheng,P. Haycock,J. Evans,R. M. Martin

DOI: https://doi.org/10.1038/s41398-024-02932-w

2024-05-30

Translational Psychiatry

Abstract:Omega-3 fatty acids have been implicated in the aetiology of depressive disorders, though trials supplementing omega-3 to prevent major depressive disorder (MDD) have so far been unsuccessful. Whether this association is causal remains unclear. We used two sample Mendelian randomization (MR) to investigate causality. Genetic variants associated with circulating omega-3 and omega-6 fatty acids in UK Biobank (UKBB, n = 115,078) were selected as exposures. The Psychiatric Genomics Consortium (PGC) genome-wide association studies (GWAS) of MDD ( n = 430,775; cases = 116,209; controls = 314,566) and recurrent depression (rMDD, n = 80,933; cases = 17,451; controls = 62,482), were used as outcomes. Multivariable MR (MVMR) models were used to account for biologically correlated lipids, such as high- and low-density cholesterol and triglycerides, and to explore the relative importance of longer-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) using data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE, n = 8866). Genetic colocalization analyses were used to explore the presence of a shared underlying causal variant between traits. Genetically predicted total omega-3 fatty acids reduced the odds of MDD (OR IVW 0.96 per standard deviation (SD, i.e. 0.22 mmol/l) (95% CIs 0.93–0.98, p = 0.003)). The largest point estimates were observed for eicosapentaenoic acid (EPA), a long-chain omega-3 fatty acid (OR EPA 0.92; 95% CI 0.88–0.96; p = 0.0002). The effect of omega-3 fatty acids was robust to MVMR models accounting for biologically correlated lipids. 'Leave-one-out' analyses highlighted the FADS gene cluster as a key driver of the effect. Colocalization analyses suggested a shared causal variant using the primary outcome sample, but genomic confounding could not be fully excluded. This study supports a role for omega-3 fatty acids, particularly EPA, in the aetiology of depression, although pleiotropic mechanisms cannot be ruled out. The findings support guidelines highlighting the importance of EPA dose and ratio for MDD and question whether targeted interventions may be superior to universal prevention trials, as modest effect sizes will limit statistical power.

psychiatry

What problem does this paper attempt to address?

The problem this paper attempts to address is the exploration of the causal relationship between omega-3 fatty acids and Major Depressive Disorder (MDD). Although observational studies suggest a negative correlation between omega-3 fatty acids and MDD, this association may be influenced by dietary habits, socioeconomic factors, and reverse causality. Additionally, the results of studies using omega-3 fatty acid supplements to prevent or treat MDD are inconsistent, partly due to differences in dosage and the ratio of omega-3 fatty acids (such as EPA and DHA).

To better understand the impact of omega-3 fatty acids on MDD, researchers utilized the Mendelian Randomization (MR) method, an epidemiological approach that can reduce the influence of confounding factors. Specifically, they used genetic variations related to circulating omega-3 and omega-6 fatty acids from the UK Biobank as exposure variables and data from the Psychiatric Genomics Consortium (PGC) as outcome variables. Through this method, the researchers aimed to determine whether omega-3 fatty acids can reduce the risk of MDD, particularly the differential effects of long-chain omega-3 fatty acids EPA and DHA, to explain the variability in intervention trials.